Research Brief | Published October 2, 2026
Looking Directly Inside the Kidney
A 52-week randomized, placebo-controlled trial published October 1 in Nature Medicine did something unusual: instead of only measuring kidney function from blood and urine tests, researchers looked directly inside the kidney — combining functional MRI, paired kidney biopsies, single-nucleus RNA sequencing, and spatial transcriptomics.
The trial, called REMODEL (NCT04865770), enrolled 106 adults with type 2 diabetes and chronic kidney disease. Participants received once-weekly semaglutide 1.0 mg or placebo for 52 weeks. The goal was not to re-prove that GLP-1 drugs help the kidney — the earlier FLOW trial (3,533 patients) already showed a 24% reduction in major kidney and cardiovascular outcomes — but to find out how.
What the Study Found — and Didn’t
The three preset MRI primary endpoints, including kidney blood oxygenation, did not change significantly. But secondary and exploratory results pointed to several possible mechanisms:
- Lower renal vascular resistance — blood flowed more easily through the kidney’s vessels;
- Less fat in and around the kidney, and stabilized cortical fibrosis;
- A calmer immune environment — biopsies showed fewer immune cells, particularly natural killer and NKT cells, around the glomeruli;
- Glomerular endothelial cells responded most strongly, showing improved metabolic and fibro-inflammatory signaling, with increased cadherin-5 suggesting repair of the filtration barrier.
Why It Matters
REMODEL moves the conversation from “GLP-1 protects the kidney” to “through which cells and tissue mechanisms it may do so.” That distinction matters for nutrition and lifestyle professionals: it suggests the drug’s benefit is not only about lower blood sugar or body weight, but about microvascular and immune pathways that diet, exercise, and metabolic health also influence.
Boundaries
This was a small, 52-week mechanistic trial; many findings were secondary or exploratory and need confirmation. Long-term kidney outcomes with semaglutide come from the larger FLOW trial, and treatment decisions still depend on each patient’s kidney function, cardiovascular risk, and medications.
Mechanisms are real. Effects have boundaries. And the easiest place to go wrong is often our own interpretation.
Professional Review: Thomas Lin（林存默）, Vice President, The Association of Certified Professional Nutritionists (ACPN)
Professional Community: ACPN — The Association of Certified Professional Nutritionists
Sources: Nature Medicine (REMODEL, NCT04865770); FLOW trial (NCT03819153).